title: U.S. Food and Drug Administration drug approval: slow advances in obstetric care in the United States.
authors.affiliation: From the University of California, Irvine, Orange, California; Cytokine Pharmasciences, King of Prussia, Pennsylvania; and ProteoGenix, Inc., Costa Mesa, California.
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Wing
authors.forename: Barbara
authors.initials: B
authors.lastname: Powers
authors.forename: Durlin
authors.initials: D
authors.lastname: Hickok
mesh_terms: D002986:Clinical Trials as Topic; D003365:Costs and Cost Analysis; D017277:Drug Approval / Q000191:economics / Q000379:methods; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D017387:Investigational New Drug Application; D016365:Liability, Legal; D009774:Obstetrics; D056687:Off-Label Use; D009965:Orphan Drug Production / Q000331:legislation & jurisprudence; D011358:Product Surveillance, Postmarketing; D014481:United States; D014486:United States Food and Drug Administration